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Abstract
The inhibitor of apoptosis protein Survivin regulates hematopoiesis, although its mechanisms of 
regulation of hematopoietic stem cells (HSCs) remain largely unknown. While investigating 
conditional Survivin deletion in mice, we found that Survivin was highly expressed in 
phenotypically defined HSCs and Survivin deletion in mice resulted in significantly reduced total 
marrow HSC and progenitor cells (HPC). Transcriptional analysis of Survivin−/− HSCs revealed 
altered expression of multiple genes not previously linked to Survivin activity. In particular, 
Survivin deletion significantly reduced expression of the Evi-1 transcription factor indispensable 
for HSC function, and the downstream Evi-1 target genes Gata2, Pbx1 and Sall2. The loss of 
HSCs following Survivin deletion and impaired long-term HSC repopulating function could be 
partially rescued by ectopic Evi-1 expression in Survivin −/− HSCs. These data demonstrate that 
Survivin partially regulates HSC function by modulating the Evi-1transcription factor and its 
downstream targets and identify new genetic pathways in HSCs regulated by Survivin.
INTRODUCTION
The endogenous inhibitor of apoptosis protein Survivin regulates apoptosis, cell division and 
cell cycle (1-3) and deregulated expression of Survivin is frequently observed in solid 
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tumors and in leukemia cells (4, 5). Survivin is the fourth most highly expressed transcript in 
cancer cells (6), where its expression is commonly associated with a higher proliferative 
index, reduced apoptosis, resistance to chemotherapy and an increased rate of tumor 
recurrence. While early studies suggested that Survivin was expressed only during 
development and in neoplastic adult cells, it is now known that Survivin is expressed in 
normal tissues, including hematopoietic stem and progenitor cells (HSPC) (7, 8), T-cells 
(9-11), neutrophils (12), erythroid cells (13) and vascular endothelial cells (14, 15). In 
addition to its role during development, Survivin plays physiologic roles in proliferation and 
cell cycle control in mouse and human, particularly in highly proliferating cell systems such 
as hematopoiesis. Despite a better understanding of where and when Survivin is expressed, 
little is currently known about the mechanism of action of Survivin in normal adult cells or 
the growth and proliferative pathways in which it participates. We found that Survivin was 
highly expressed in primitive mouse hematopoietic stem cells (HSC) and conditional 
deletion caused hematopoietic collapse. To gain insight into Survivin function in 
hematopoiesis, particularly in HSC, we performed differential mRNA microarray analysis 
on mouse HSC shortly following conditional Survivin deletion. Survivin deletion was 
associated with a significant reduction in the expression of the transcription factor Evi-1 and 
its downstream target genes Gata2, Pbx1 and Sall2, transcription factors critical for normal 
hematopoiesis. Ectopic expression of Evi-1 in HSC significantly rescued the hematopoietic 
collapse due to the loss of Survivin in vivo. These studies provide the first mechanistic 
insight of the role of Survivin in regulating genetic pathways required for HSC function.
MATERIALS AND METHODS
Animals
SPF female C57Bl/6 mice between 6-8 weeks of age were purchased from the Jackson 
Laboratories (Bar Harbor, Maine). B6.SJL-PtrcAPep3B/BoyJ (B6.BoyJ) mice were bred at 
Indiana University. Mice in which the Survivin gene could be conditionally deleted by 
Tamoxifen (CreER-Survivinfl/fl) (16) or polyI:polyC (Mx1-Cre Survivinfl/fl) (17) were 
previously described. Littermate Survivinfl/fl mice without Cre were used as controls. PCR 
primers used to distinguish the wild-type, floxed or deleted Survivin alleles were prepared as 
described (9). The IACUC of Indiana University School of Medicine and Shimane 
University School of Medicine approved all experimental procedures.
Antibodies and cytokines
The following antibodies were purchased from BD Biosciences (San Diego, CA): anti-Fcγ-
III/II receptor; APC-conjugated anti-mouse c-kit (clone 2B8); R-Phycoerythrin (PE)-
conjugated anti-mouse CD3 (clone 143-2C11), GR-1 (clone RB6-8C5), B220 (clone 
RA3-6B2), Mac1 (clone M1/70) and Ter119 (clone Ter119); fluorescein isothiocyanate 
(FITC)-conjugated CD45.2 and PE-conjugated CD45.1; rat IgG2a; rat IgG2b and hamster 
IgG. Biotinylated lineage markers consisting of CD5, CD11b, Gr-1, 7-4 and Ter119 were 
purchased from Miltenyi Biotech (Auburn, CA). Recombinant human (rh) Flt3 ligand (FL), 
rh thrombopoietin (Tpo) and recombinant mouse stem cell factor (rmSCF) were purchased 
from R&D Systems (Minneapolis, MN). Recombinant murine GM-CSF (rmGM-CSF) was 
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purchased from BioVision (Palo Alto, CA). Recombinant human erythropoietin was 
purchased from Amgen (Thousand Oaks, CA).
In vivo deletion of the Survivin gene
Survivinfl/fl and CreER-Survivinfl/fl mice received 5 mg Tamoxifen in corn oil (Sigma-
Aldrich, St Louis, MO) intraperitoneally (i.p.) for 3 consecutive days, rested for 3 days, 
treated for an additional 3 days with Tamoxifen at the same dose and analyzed at 14 days 
following the final administration of Tamoxifen. Mx1-Cre Survivinfl/fl mice received 3 
injections of 260 µg/mouse polyI:polyC (GE HealthCare Bioscience, Piscataway, NJ) i.p. 
every other day (days 1,3,5) and analyzed 14 days later. Red blood cells (RBC), platelets 
(PLT) and the absolute neutrophil count (ANC) were quantified using a Hemavet 950F 
hematology analyzer (Drew Scientific, Oxford, CT). Total nucleated cellularity was 
quantitated and marrow or spleen HSPC analyzed using flow cytometry and CFC analysis. 
For CFC analysis, cells were cultured in methylcellulose medium containing growth factors 
as described (18) . Colonies were scored after 7 days.
Retrovirus transduction and competitive HSC transplants
Bone marrow cells from Cre-Survivinfl/fl and Survivinfl/fl mice were transduced with 
ecotropic retrovirus generated using Phoenix Eco cells and MSCV (-) or mouse Evi-1 
cDNA. Briefly, lineage-depleted marrow cells were pre-stimulated with 100 ng/ml of rhTpo, 
rmSCF and rhFL for 48 hours and were then infected with fresh retrovirus supernatant 
containing MSCV(-) or MSCV-Evi-1 (19) for 2 consecutive days. Transduced marrow cells 
from CreER-Survivinfl/fl and Survivinfl/fl mice were cultured in IMDM/10% FBS with 100 
ng/ml of rhTpo, rmSCF and rhFL in the presence of 1 μM of 4OH-Tamoxifen (Sigma-
Aldrich) for 7 days. Viable cells were enumerated by trypan blue exclusion and stained with 
antibodies against c-kit, Sca-1, lineage markers and CD34. For competitive transplantation 
assays, bone marrow cells from untreated Mx1-Cre Survivinfl/fl and Survivinfl/fl mice 
(CD45.2) were mixed with bone marrow cells from B6.BoyJ mice (CD45.1) and 1x106 cells 
transplanted into lethally irradiated (1050 cGy) C57Bl/6 mice (CD45.2). Transduced cells 
(CD45.2) were cultured in IMDM/10% FBS with 100 ng/ml of rhTpo, rmSCF and rhFL for 
48 hrs, mixed with CD45.1 competitor bone marrow cells and 1x106 cells transplanted into 
lethally irradiated (1050 cGy) C57Bl/6 mice (CD45.2). At 8 weeks post-transplantation, 
Survivin gene deletion was induced as described above. The proportion of CD45.1 and 
CD45.2 cells in peripheral blood was determined monthly by flow cytometry.
cDNA microarray and quantitative RT-PCR
Bone marrow cells were harvested from control Survivinfl/fl and CreER-Survivinfl/fl mice at 
14 days post Survivin gene deletion, stained with anti-CD34, c-kit, Sca-1 and lineage 
markers, and CD34neg KSL cells were isolated by FACS. Sorted cells were immediately 
lysed and subjected to differential mRNA microarray analysis, which was performed by 
Miltenyi Biotec (Auburn, CA). Briefly, 250 ng of each cDNA was used as a template for 
Cy3 and Cy5 labeling. Equal amounts of corresponding Cy3- and Cy5-labeled cDNAs from 
Tamoxifen-treated Survivinfl/fl and CreER-Survivinfl/fl mice were combined and hybridized 
overnight (17 hours, 65°C) to Agilent Whole Mouse Genome Oligo Microarrays (44K). 
Fluorescence signals of the hybridized microarrays were detected using Agilent's DNA 
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microarray scanner (Agilent, Palo Alto). The Agilent Feature Extraction Software (FES) was 
used to determine feature intensities and ratios (including background subtraction and 
normalization), rejects outliers and calculates statistical confidences (p-values). The 
differentially expressed genes were functionally classified according to their molecular 
function and role in biological processes, as defined by Gene Ontology (http://
www.geneontology.org/) or the molecular pathways defined by the KEGG database (http://
www.genome.jp/kegg/) using the DAVID program (the Database for Annotation, 
Visualization and Integrated Discovery; http://david.abcc.ncifcrf.gov/home.jsp) (20). The 
pathways and the molecular network regulated by Survivin were visualized using Cytoscape 
software (http://www.cytoscape.org/) (21). In separate experiments, total RNA isolated from 
the sorted control and Survivin-deleted CD34neg.KSL cells was used for quantitative RT-
PCR using platinum SYBR Green qPCR SuperMix UDG (Invitrogen, Carlsbad, CA). 
Primers for the RT-PCR experiments are listed in Supplementary Table 1. Differences in 
mRNA were calculated using the ΔCT method and were normalized to HPRT, as previously 
described (7).
Statistics
The data are expressed as the mean ± standard error (SEM). Statistical differences between 
single agents and the control were determined using the two-tailed Student's t-test in 
Microsoft Excel ™ (Microsoft Corp, Seattle, WA). The correlation of gene expression with 
Survivin was determined by Pearson's correlation analysis using Microsoft Excel ™.
RESULTS
Survivin is expressed in mouse HSCs and disruption impairs hematopoiesis
We previously demonstrated that Survivin is expressed in the human CD34+ cell population 
that contains HSC (7, 22), and is critical for CD34+ cell proliferation and survival (7, 8, 23). 
It was also shown that Survivin deletion in mice impairs hematopoiesis (17). However, the 
expression of Survivin in primitive mouse HSC and the consequences of Survivin deletion 
on HSC function have not been studied. We now show using RT-PCR analysis that mouse 
Survivin mRNA is expressed in the CD34neg KSL cell population that is enriched for long-
term repopulating HSC and in the KSL cell population that contains HSC and HPC (Figure 
1A-Upper Panel). In addition, the mouse Survivin-121 splice variant that also demonstrates 
anti-apoptotic activity (24) was also expressed in mouse HSC and HPC, but at significantly 
lower levels compared to full length Survivin (Figure 1A, Lower Panel). Consistent with the 
high expression of Survivin in CD34neg KSL cells, analysis of the public gene expression 
profile database GSE 4332 (www.ncbi.nlm.nih.gov/geo) showed that the Survivin signal was 
similarly expressed in mouse bone marrow Flt3 (CD135) neg CD34 neg KSL cells highly 
enriched for primitive HSC (25) (Figure 1B). Survivin was also detected in CD34 pos KSL 
cells that represent proliferating HPC, consistent with our previous demonstration of 
Survivin up regulation during cell cycle (7, 8).
Peripheral blood white blood cells (WBC), red blood cells, marrow and spleen cellularity or 
the proportion or total number of lineage-committed cells (Gr-1+, Mac-1+, B220+, CD4+ and 
CD8+) in the bone marrow or peripheral blood of CreER-Survivinfl/fl mice were within 
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normal ranges at 14 days after Survivin deletion with the exception of a significant reduction 
in platelet count (Table 1). In contrast, Survivin deletion significantly decreased the 
frequency and the absolute number of primitive CD34neg KSL cells containing HSC 
(61±5% reduction compared to Survivinfl/fl mice receiving the same treatment) (Figure 1C, 
D) and also reduced total bone marrow linneg cells (37±6%), KL cells (35±8%) and total 
CFC (44±6%) (Figure 1D). Similar to bone marrow, total CFC in the spleen of Tamoxifen 
treated CreER-Survivinfl/fl mice were decreased by 62±12% (Figure 1E).
To further evaluate the functional role of Survivin in HSC regulation; we performed long-
term competitive repopulating assays. Lethally irradiated C57Bl/6 mice were transplanted 
with 1x106 cells consisting of congenic B6.BoyJ (CD45.1) marrow cells plus marrow cells 
(CD45.2) from Survivinfl/fl or Mx1-Cre Survivinfl/fl mice at ratios from 1:1 to 0.5:1. At 1 
month post-transplant, the levels of CD45.2/CD45.1 chimerism observed (1:1 ratio shown) 
were at the expected ratios and were equivalent in all transplant recipients (Figure 1F; Left 
panels)(Supplemental Figure 1A, 1B). Following Survivin deletion, a significant and 
progressive reduction in donor CD45.2 chimerism derived from Mx1-Cre Survivinfl/fl bone 
marrow cells was observed (Figure 1F, Center Panel)(Supplemental Figure 1A, 1B) as 
previously described (17). Analysis of T, B and myeloid cells in peripheral blood showed 
equal reduction in all lineages (Figure 1F, Right Panel). In addition to reduced contribution 
to chimerism, the absolute number of Survivin gene-deleted donor derived CD34negKSL 
cells in the recipient mice marrow 20 weeks post-transplant (16 weeks post polyI:polyC 
treatment) was also significantly lower compared to donor cells derived from Survivin fl/fl 
control mice (Figure 1G). These data confirm a significant role for Survivin in regulation of 
hematopoiesis, indicating that it is essential for HSC maintenance and function.
Survivin modulates the expression of genes associated with divergent molecular 
functions in mouse HSC
To identify downstream pathways regulated by Survivin in HSC, mRNA expression in 
FACS sorted CD34negKSL cells before and after Survivin deletion were compared using 
cDNA microarrays. In two separate experiments, we found 1,653 transcripts that were 
differentially regulated in CD34neg KSL cells upon Survivin deletion, 965 down-regulated 
and 688 up-regulated. The full list of Survivin regulated genes has been deposited in the 
public domain. Birc5 (Survivin) mRNA was reduced by an average 10.4±0.2-fold 
(P<0.001), confirming the efficacy of Survivin deletion. Significantly regulated genes (>/< 
2-fold) were classified into 35 clusters according to the Gene Ontology Database (Figure 
2A). The 11 functional categories containing the greatest number of genes among the 35 
groups are boxed (Figure 2A) and shown separately in Figure 2B. The circles in Figure 2 
indicate individual functions, and the lines between functional groups represent the presence 
of shared genes. Survivin disruption altered the expression of genes regulating cell cycle and 
cell division, as expected based on the known mechanism of action studies (shown with 
asterisks in Figure 2A). However, analysis of gene functional categories revealed that 
Survivin deletion also affected the expression of genes associated with transcription, protein 
localization, translation, nucleotide binding and RNA processing, functions not previously 
linked to Survivin activity (Figure 2A, B). Comparison of our microarray data with the list 
of previously reported mouse HSC-associated genes (26) identified a number of these genes 
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that were differentially modulated by Survivin depletion (Figure 2C). Expression of several 
transcription factors associated with embryogenesis, hematopoiesis and cell fate 
determination, including the homeobox transcription factors HoxA5 and Hoxb1, HIF1α, 
Evi-1, Foxc1, Pbx1, Gata2 and Sall2 were altered as a consequence of Survivin deletion in 
CD34neg KSL cells. To validate the microarray data, QRT-PCR analysis was performed on 
pairs of CD34neg KSL cells from Survivinfl/fl and CreER-Survivinfl/fl mice (Table 2) 
following Survivin deletion. An 8.5-fold reduction in Evi-1 transcripts as well as transcripts 
of several downstream Evi-1 target genes was observed , including Gata2, which regulates 
HSC proliferation/self-renewal (27, 28); Pbx1(29), that maintains HSCs quiescence (30); 
and Sall2 that affects committed myeloid progenitor cell differentiation and myeloid cell 
maturation (31, 32). The Foxc1 transcript was up regulated by Survivin deletion, consistent 
with a reported inverse relationship with Pbx1 (33). In addition to the fact that Gata2, Pbx1 
and Sall2 are transcriptional targets of Evi-1, analysis of genes in the public mouse KSL cell 
gene expression database (GSE 2031, www.ncbi.nlm.nih.gov/geo) (34) showed a strong 
correlation between Survivin (Birc5) and Evi-1(r=0.35, N=44, P<0.05) and similar to mouse 
HSC, Survivin showed a positive correlation (r=78) with Evi-1 in highly purified human 
HSC (Gene expression Omnibus:www.ncbi.nlm.nih.gov/geo (35).
Survivin Regulates HSC Function through Evi-1
Differential expression of transcription factors upon Survivin deletion was an unexpected 
result, since a direct role for Survivin in regulating mammalian gene transcription has not 
been reported. However, Bir1, the C. elegans homologue of Survivin, can function as a 
transcriptional regulator (36) and Survivin has been shown to affect the expression of 
multiple genes in cancer cells (37-39). Since a strong correlation was seen between Survivin 
deletion and reduction in Evi-1 as well as Evi-1 downstream targets genes, we focused on 
evaluating a potential Survivin/Evi-1 functional axis in regulating HSC function. We 
hypothesized that restoration of Evi-1 signaling in HSC would restore or protect impaired 
hematopoiesis resulting from Survivin deletion. Survivin deletion in bone marrow cells from 
CreER-Survivinfl/fl mice transduced with retroviruses containing MSCV vector resulted in an 
almost total reduction in the number of KSL cells (Figure 3A Top) and CD34neg KSL cells 
(Figure 3A Bottom; Survivin in +/+ vector [Bar 1] vs. Survivin −/− vector [Bar 3]). In 
contrast, significantly more KSL and CD34neg KSL cells were observed when Survivin was 
deleted in bone marrow cells ectopically expressing Evi-1 (Figure 3, N=3, P<0.05; 
Survivin −/− vector [Bar 3] vs. Survivin −/− Evi-1[Bar 4]). The enhancing effect of ectopic 
Evi-1 in Survivin deleted bone marrow cells was not observed in control Survivinfl/fl bone 
marrow cells (Survivin +/+ vector [Bar 1] vs. Survivin +/+Evi-1 [Bar 2].
Next, marrow cells from Survivinfl/fl or Mx1-Cre Survivinfl/fl mice (CD45.2) were 
transduced with MSCV vector or human Evi-1 cDNA and subsequently transplanted along 
with competitor marrow cells (CD45.1) into lethally irradiated congenic mice. At 8 weeks 
post-transplantation prior to induction of Survivin gene deletion, there were no significant 
differences in peripheral blood chimerism between Evi-1 and vector control treatments 
(Figure 3B; Top Panel). However, upon deletion of Survivin selectively in donor cells, a 
significant reduction of CD45.2 donor cell chimerism was observed over time as expected 
(Figure 3B Bottom Survivin +/+ [Bar 1] vs. Survivin −/− [Bar 2]). In contrast, significantly 
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higher chimerism was observed for donor cells lacking Survivin but expressing ectopic 
Evi-1, compared to Survivin-deleted cells (Figure 3B Survivin −/− vector [Bar 2] vs. 
Survivin −/− Evi-1[Bar 3]). The competitive repopulating units (CRU) of the donor cells 
expressing Evi-1 was elevated by 17±2-fold in comparison to cells lacking Survivin and 
without Evi-1 (P<0.0001). None of the recipient mice developed signs of leukemia or died 
during a 6-month follow up period.
DISCUSSION
Survivin is expressed during development and elevated re-expression is a hallmark of 
neoplastic cells, associated with neoplastic growth, high proliferative index and resistance to 
chemotherapy (1, 2). Increasing evidence also indicates that Survivin plays physiological 
roles in normal cell division, including hematopoiesis (3), however little is known regarding 
signaling or functional pathways through which Survivin regulates normal cell growth.
While we have previously shown that Survivin is expressed in normal human CD34+ stem 
and progenitor cells and is required for cell cycle entry and progression, and survival (7, 22, 
23), and others have demonstrated that conditional gene deletion in mice alters steady-state 
hematopoiesis (17), a direct functional role in HSC, and downstream mechanistic targets 
have not been identified. While basal Survivin expression is low in mouse HSC compared to 
less quiescent hematopoietic populations, as we previously described for human HSCs (7, 
23), the catastrophic effect of Survivin deletion became highly notable upon HSC stress due 
to transplantation. This suggests that Survivin activity or molecular networks that associate 
with Survivin in HSC critically modulate HSC fate/function. We now demonstrate that 
Survivin is essential for normal long-term repopulating HSC function and identify 
differentially expressed genes associated with HSC function, as well as a number of 
biological pathways not previously linked to Survivin activity. Surprisingly, Survivin 
deletion significantly down-regulated the expression of Evi-1, a transcriptional factor 
selectively expressed in HSC and indispensable for HSC function (40). Over expression of 
Evi-1 in HSC compensated, for the impaired HSC function caused by Survivin deletion.
Conditional Evi-1 knock-down in mice has been shown to reduce marrow KSL and 
CD34negKSL cells without affecting differentiation of mature blood cells (31). We also 
observed marginal but significant reduction in platelets in both the Evi-1 (31) and Survivin 
conditional knockout mice (Table 2). The embryonic lethality of Survivin knockout mice is 
also consistent with the Evi-1 phenotype (41). These findings suggest that Survivin regulates 
hematopoiesis similarly to Evi-1. In addition to Evi-1, Survivin knock-down reduced the 
expression of Gata2, Pbx1 and Sall2 in HSC, which are transactivated by Evi-1 and 
necessary for normal hematopoietic function (31). The shared regulation of these genes by 
Evi-1 and Survivin is consistent with the reduction of Evi-1 expression following Survivin 
deletion. In contrast, Evi-1 deletion had no effect on Survivin expression in mouse HSC (31)
(GSE11557); suggesting Survivin is upstream of Evi-1. Importantly, marrow cells derived 
from conditional Survivin−/− mice expressing ectopic Evi-1 showed significantly enhanced 
numbers of CD34negKSL cells and competitive repopulating activity in comparison to cells 
in which Survivin was ablated without Evi-1 expression, indicating that Survivin regulates 
HSC function at least in part through modulation of Evi-1 and that repression of Evi-1 
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expression is not secondary to the cell cycle alteration and/or apoptosis resulting from 
Survivin ablation in HSC.
Ectopic expression of Evi-1 only partially rescued the hematopoietic deficits caused by 
Survivin deletion, suggesting that Evi-1 is necessary but not sufficient for full Survivin 
activity. Evi-1 can repress transcription of PTEN, which regulates HSC function (42) and 
correlates with Survivin expression in CD34+CD38− cells in patients with AML (43). Our 
microarray data showed that Survivin deletion up-regulated PTEN mRNA expression by 
~1.4-3.0 fold, however, it did not reach statistical significance. Despite the parallel change 
in Gata2 expression following Survivin deletion, ectopic Gata2 failed to compensate for the 
hematopoietic defects impaired by Survivin deletion (not shown). This however, is 
consistent with previous reports showing that the forced expression of Gata2 blocks 
hematopoiesis (44). Recent studies indicate that Survivin regulates not only cell division/cell 
cycle but also intracellular signaling (45). Our microarray data suggests that Survivin 
impacts multiple signaling pathways including transcription, protein localization and 
translation in CD34negKSL cells. While some gene alterations may represent changes in cell 
cycle and/or apoptosis upon Survivin deletion, these findings support the concept that 
Survivin is involved in divergent HSC cellular functions. Functional grouping informatics 
analysis revealed that genes associated with transcription were significantly enriched among 
those regulated by Survivin. Although there is no evidence that Survivin directly regulates 
gene transcription, Bir1, the C. elegans homologue of Survivin, has been shown to regulate 
transcription (36), Survivin expression affects transcription in cancer cells (37-39) and 
transgenic expression of Survivin alters expression of multiple genes in the bladder (46). A 
transcription factor binding analysis revealed several binding sequences for transcriptional 
factor Sp1 on the 5’ non-coding region of the mouse Evi-1 gene (GRCm38.p2 C57BL/6J; 
NC_00069). Survivin has been shown to modulate DNA binding activity of Sp1 by 
enhancing its phosphorylation (37). These findings suggest that Sp1 may be involved in the 
transcriptional regulation of Evi-1 expression by Survivin.
A previous report has indicated that induced Survivin deletion in Mx1-Cre Survivinfl/fl mice 
led to bone marrow ablation, loss of HSPC and rapid mortality (17). Although we observed 
a significant reduction in CD34negKSL cells in conditional CreER-Survivinfl/fl mice, all mice 
survived for at least 6 months. This difference may relate to either the incomplete deletion of 
the Survivin gene by Tamoxifen or to strain differences. Alternatively, the induction of 
interferons, which are known inhibitors of hematopoiesis (47, 48), by treatment with 
polyI:polyC (49, 50) in vivo, may have synergistically inhibited HSC in the previous study 
(17). Nevertheless, although the effect of Survivin gene deletion was not identical, both 
model systems clearly demonstrated the catastrophic consequences of Survivin deletion on 
HSC function.
In summary, Survivin regulates HSC proliferation through Evi-1. In addition to Evi-1, genes 
associated with transcription, cell cycle and those with divergent functions may function as 
effectors of Survivin activity in HSC. Presently, it is not clear if Survivin regulates genes 
differentially in normal versus leukemic HSC. This could highlight beneficial pathways for 
treatments aimed to protect normal HSC and therapeutically leukemic HSC.
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Figure 1. Survivin is expressed in mouse HSC and disruption of Survivin impairs their function
A. Left Panel, Top: RT-PCR for Survivin mRNAs in FACS sorted KSL and CD34negKSL 
bone marrow cells. GAPDH was used as an internal control. NC represents the negative 
control containing no template. Bottom: Quantitative analysis of wild-type Survivin and 
Survivin-121 in hematopoietic cell populations. † = significant reduction of Survivin-121 
compared to full length Survivin in respective cell type, P<0.05.
B. Survivin expression in CD34neg Flt3 neg KSL, CD34pos Flt3 neg KSL, CD34pos Flt3 high 
KSL and CD34pos KSL cells from GSE 4322, (www.ncbi.nlm.nih.gov/geo).
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C. Top: Gating criteria for isolation of CD34neg KSL cells. Bottom: RT-PCR analysis for 
floxed and deleted Survivin alleles in Survivinfl/fl and CreER-Survivinfl/fl mice following 
Tamoxifen treatment. The data are representative of 3 independent experiments.
D. Left panel: The absolute number of CD34negKSL cells per 2 femurs in Survivinfl/fl and 
CreER-Survivinfl/fl and Mx1-Cre Survivinfl/fl mice before and after Survivin deletion, 
determined by multiplying the absolute total nucleated cell number in 2 femurs by the 
percentage of CD34negKSL cells. Data represent the mean ± SEM from 3 independent 
experiments. *P<0.05. Right panel: The percent reduction of total nucleated marrow cells, 
lineage+ cells (Lin+), lineage- (Lin-) cells, c-kit+ lin- (KL) cells, CFC (CFU-GM, BFU-E, 
CFU-GEMM) and CD34negKSL cells in bone marrow obtained from Tamoxifen treated 
CreER-Survivinfl/fl and Survivinfl/fl mice. Data are the mean ± SEM of 3 independent 
experiments. *P<0.05
E. Mean total CFC/spleen ± SEM, in spleen of 3 individual mice, each assayed individually. 
*P<0.05
F. Left panel: Representative staining for nucleated peripheral blood CD45.1 and CD45.2 
cells in recipient C57Bl/6 mice transplanted with donor (CD45.2) (Survivinfl/fl or Mx1-Cre 
Survivinfl/fl) and competitor cells (CD45.1) at a ratio of 1:1. Peripheral blood was harvested. 
Peripheral blood chimerism in the recipients receiving Survivinfl/fl marrow cells (left plots) 
or Mx1-Cre Survivinfl/fl marrow cells (right plots) at 4 weeks post-transplant prior to 
polyI:polyC injection (top) and at 20 weeks, 16 weeks after polyI:polyC injection (bottom).
Center panel: Donor (CD45.2) chimerism in the recipients transplanted with Survivinfl/fl 
marrow cells (red squares) or Mx1-Cre Survivinfl/fl marrow cells (blue diamonds) at 4 
weeks post-transplantation prior to polyI:polyC treatment and at 4 week intervals thereafter. 
*P<0.05 (N=10).
Right panel: Tri-lineage analysis for donor derived (CD45.2) T, B and myeloid cells in 
recipient mice at 20 weeks post-transplant. Mean ± SEM; N= 10 mice/group, each assayed 
individually).
G. The frequency of CD34negKSL cells in the bone marrow of recipient mice was 
determined at 24 weeks post transplantation (20 weeks post polyI:polyC treatment). *P<0.05 
(N=10)
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Figure 2. Functional gene networks regulated by Survivin in mouse CD34negKSL cells
A. Genes significantly regulated by Survivin in three independent microarray analyses 
(P<0.05) were functionally classified according to the biological process and molecular 
function listed in the Gene Ontology database, and the analysis was performed using 
DAVID software (20) and visualized using the Cytoscape program (21). Genes for which 
annotations could not be assigned were excluded. A circle (node) indicates individual 
functions, and the line (edge) indicates the presence of shared genes between each functional 
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group. Functional categories are boxed and also shown in Figure 2B. Asterisks indicate 
functions related to the cell cycle and cell division for which Survivin has been implicated.
B. The panel shows the 11 functional categories containing the greatest number of genes 
among the 35 groups. The size of each circle represents the number of genes involved in 
each functional category, and the thickness of the line indicates the number of genes shared 
between given functions. Green or yellow circles represent functions defined by biological 
process or molecular function, respectively.
C. Heat map for mouse HSC-specific genes (26) found to be differentially modulated by 
Survivin depletion in CD34negKSL cells.
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Figure 3. Effect of ectopic Evi-1 expression on the in vitro proliferation of CD34negKSL cells and 
the long-term repopulating activity of HSC lacking Survivin
A. Bone marrow cells from CreER-Survivinfl/fl and control Survivinfl/fl were retrovirally 
transduced with MSCV (-) or MSCV containing human Evi-1 (19) and cultured with 100 
ng/ml each of rhTpo, rmSCF and rhFL in 10% FBS/IMDM containing 1μM of 4OH-
Tamoxifen for 7days. Top panel: KSL cells and Bottom panel: CD34negKSL cells were 
quantified by cell enumeration and flow cytometry (* P<0.05, N=3). Middle panel: 
Expression of ectopic human Evi-1 and GAPDH (as an internal control) determined by RT-
PCR.
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B. Peripheral blood chimerism in (CD45.1) recipients transplanted with (CD45.2) Mx1-Cre 
Survivinfl/fl cells expressing vector control or Evi-1or Survivinfl/fl marrow cells. 
PolyI:polyC was injected (i.p.) at 8 weeks post-transplantation. The proportion of CD45.2 
cells before polyI:polyC injection (8 week, Top panel) and 24 weeks (Bottom panel) after 
polyI:polyC treatment are shown (*P<0.05 N=10).
Fukuda et al. Page 18
Leukemia. Author manuscript; available in PMC 2015 August 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Fukuda et al. Page 19
Table 1
Effects of Tamoxifen treatment on cells in peripheral blood, bone marrow and spleens of control Survivin fl/fl 
and Cre-ER Survivin fl/fl mice
Peripheral Blood
Group WBCa RBCb Plta
Survivin fl/fl 5.6±0.5 9.4±0.6 1607±103
Cre-ER Survivin fl/fl 6.4±1.6 9.8±0.6 1041±196*
Mac-1a GR-1a Ter199a CD4a CD8a B220a
Survivin fl/fl 1.9±0.2 2.0±0.3 1.2±0.3 1.2±0.1 0.5±0.04 1.1±0.1
Cre-ER Survivin fl/fl 2.1±0.5 2.4±0.6 2.9±0.9 1.3±0.3 0.5±0.2 2.6±1.3
Bone Marrow
TNCc Mac-1d GR-1d Ter199d
Survivin fl/fl 3.2±0.4 62±3 61±3 24±10
Cre-ER Survivin fl/fl 3.1±0.2 31±4 61±4 28±6
Spleen
TNCe
Survivin fl/fl 207±21
Cre-ER Survivin fl/fl 174±13
Control and Survivin fl/fl and Cre-ER Survivin fl/fl mice were treated with Tamoxifen as described in the Method section. CBC and bone marrow 
and spleen cellularity were determined using a Hemavet hematology analyzer and flow cytometry at 14 days after gene deletion.
a
×103 per MicroL
b
×106 per MicroL
c
×107/2 femurs
d% of total marrow cells
e
×106/spleen
*
P<0.05
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Table 2
Genes modulated by Survivin deletion and implicated in HSC function
Gene symbol Fold change by array Fold change by RT-PCR Gene name [GenBank Accession number]
Birc5 −10.5 −20.0 Survivin [NM_009689]
Evi-1 −4.4 −8.5 Ecotropic viral integration site [NM_007963]
Gata2 −14.4 −11.1 GATA binding protein 2 [NM_008090]
Pbx1 −33.7 −12.5 pre B-cell leukemia transcription factor 1 [AK144446]
Sall2 −2.2 −33.3 sal-like 2 [NM_015772]
Hoxa5 −10.9 −3.8 homeo box A5 [NM_010453]
Egr1 −4.8 −2.5 early growth response 1 [NM_007913]
Tie1 −2.9 −4.6 tyrosine kinase receptor 1 [NM_011587]
Robo4 −5.3 −6.4 roundabout homolog 4 (Drosophila) [NM_028783]
Hif1α 2.3 4.1 hypoxia inducible factor 1, alpha subunit [NM_010431]
FoxC1 4.5 ND Forkhead box C1 [NM_008592]
Selected genes whose expression was affected by Survivin deletion in mouse CD34negKSL cells. Microarray data represent the average of three 
independent experiments, and the fold change is shown. Quantitative RT-PCR data are the average for three separate experiments using the ΔΔCt 
method with the fold change compared to HPRT (P <0.05). ND: not determined.
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